Want to see KR:000640 full AI Analyst Report?

Dong-A Socio Holdings Co., Ltd. (000640) Price & Analysis

― Followers

000640 Stock Chart & Stats

₩87600.00

-₩900.00(-1.02%)

Oct 28, 2026

―

Day’s Range― - ―

52-Week Range₩74,500.00 - ₩121,844.69

Previous CloseN/A

VolumeN/A

Average Volume (3M)9.04K

Market Cap

₩581.17B

Enterprise Value₩1.03T

Total Cash (Recent Filing)₩214.40B

Total Debt (Recent Filing)₩687.36B

Price to Earnings (P/E)6.9

Beta0.13

Next Earnings

Feb 15, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.94%

Share Statistics

EPS (TTM)12512.15

Shares Outstanding6,732,527

10 Day Avg. Volume11,612

30 Day Avg. Volume9,043

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)0.63

Price to Sales (P/S)0.50

P/FCF Ratio4.65

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)11,146.33

Revenue Forecast (FY)₩1.59T

Bulls Say, Bears Say

Bulls Say

Revenue Growth And ProfitabilityThe group combines continued revenue expansion with solid gross and EBITDA margins, indicating a functioning portfolio of healthcare businesses with underlying operating scale. This earnings base can support reinvestment and strategic development, although conversion to net income remains less consistent.

Improving Balance SheetManageable and improving leverage strengthens financial flexibility across the holding-company structure. Growing equity alongside assets provides a more stable foundation for subsidiaries, investment decisions, and downturn absorption, while reducing the balance-sheet pressure associated with previously higher debt levels.

Contract Manufacturing ExpansionThe BTGIN contract provides visible demand for the group’s outsourced pharmaceutical manufacturing capabilities and reinforces its position in contract production. Advance payment terms and possible extension add commercial support, while the subsidiary platform can broaden revenue beyond traditional pharmaceutical activities.

Bears Say

Choppy Net MarginsModerate and uneven net margins indicate that revenue growth does not consistently translate into bottom-line earnings. This can limit internal funding capacity and make results more sensitive to operating costs, subsidiary performance, and the mix of healthcare businesses within the portfolio.

Volatile Cash GenerationCurrent positive free cash flow supports earnings quality, but the history of negative or very low free cash flow shows that conversion is not consistently dependable. Working-capital swings or investment cycles could therefore constrain shareholder distributions, debt reduction, or funding for expansion.

Sequential Operating Profit PressureThe latest provisional results show that strong sales growth is accompanied by weaker sequential operating profit, pointing to pressure on near-term operating leverage. If this pattern persists, it could delay margin improvement and reduce the earnings benefit of continued expansion across the group.

Dong-A Socio Holdings Co., Ltd. News

Dong-A Socio Holdings Plans NDR to Detail Q3 Results and Affiliate Management

Dong-A Socio Holdings Co., Ltd. ( ($KR:000640) ) has issued an update. Dong-A Socio Holdings, via Dong-A Pharm,...

2d ago

Dong-A Pharm Posts Strong Sales Growth but Softer Operating Profit in Provisional Q3 Results

The latest announcement is out from Dong-A Socio Holdings Co., Ltd. ( ($KR:000640) ). Dong-A Pharm, under Dong-A...

2d ago

Dong-A Subsidiary BTGIN Wins KRW 13.5 Billion Drug Manufacturing Contract

Dong-A Socio Holdings Co., Ltd. ( ($KR:000640) ) has provided an announcement. BTGIN Co., Ltd., a subsidiary of...

13d ago

Dong-A Socio Wins Shareholder Backing for Strategic Article Changes and Pet, Health Expansion

An update from Dong-A Socio Holdings Co., Ltd. ( ($KR:000640) ) is now available. Dong-A Socio Holdings has...

1M ago

000640 FAQ

What was Dong-A Socio Holdings Co., Ltd.’s price range in the past 12 months?

Dong-A Socio Holdings Co., Ltd. lowest stock price was ₩74500.00 and its highest was ₩121844.69 in the past 12 months.

What is Dong-A Socio Holdings Co., Ltd.’s market cap?

Dong-A Socio Holdings Co., Ltd.’s market cap is ₩581.17B.

When is Dong-A Socio Holdings Co., Ltd.’s upcoming earnings report date?

Dong-A Socio Holdings Co., Ltd.’s upcoming earnings report date is Feb 15, 2027 which is in 109 days.

How were Dong-A Socio Holdings Co., Ltd.’s earnings last quarter?

Dong-A Socio Holdings Co., Ltd. released its earnings results on Jul 27, 2026. The company reported ₩4324 earnings per share for the quarter.

Is Dong-A Socio Holdings Co., Ltd. overvalued?

According to Wall Street analysts Dong-A Socio Holdings Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dong-A Socio Holdings Co., Ltd. pay dividends?

Dong-A Socio Holdings Co., Ltd. pays a Semiannually dividend of ₩700 which represents an annual dividend yield of 1.94%. See more information on Dong-A Socio Holdings Co., Ltd. dividends here

What is Dong-A Socio Holdings Co., Ltd.’s EPS estimate?

Dong-A Socio Holdings Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Dong-A Socio Holdings Co., Ltd. have?

Dong-A Socio Holdings Co., Ltd. has 6,732,527 shares outstanding.

What happened to Dong-A Socio Holdings Co., Ltd.’s price movement after its last earnings report?

Dong-A Socio Holdings Co., Ltd. reported an EPS of ₩4324 in its last earnings report. Following the earnings report the stock price went up 0.683%.

Which hedge fund is a major shareholder of Dong-A Socio Holdings Co., Ltd.?

Currently, no hedge funds are holding shares in KR:000640

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Dong-A Socio Holdings Co., Ltd.

Dong-A Socio Holdings Co., Ltd., established in Seoul, South Korea in 1932, maintains a prominent role in the pharmaceutical industry both within South Korea and globally. Its diverse product range includes well-known items such as Bacchus, Benachio, and Tempo, alongside various infection management solutions and advanced imaging equipment like the FX-V1 and CLS-S7, which are utilized for surgical and diagnostic purposes. Beyond healthcare, the company offers a selection of beverages, including Gayasan Cheonnyeonsu mineral water, POCARI SWEAT, Narangd cider, Oronamin C, and Oran-C bio-PET. Demonstrating a commitment to innovation, Dong-A Socio Holdings is also developing an mRNA-based COVID-19 vaccine, STP2104, which is currently undergoing Phase I clinical trials. The company provides a wide array of services, encompassing business management, contract manufacturing (CMO) for antibodies and recombinant proteins through pre-clinical studies, clinical trials, and commercial production. Other services include maintenance, repair, and operation (MRO), quarantine, military logistics, and packaging and parcel delivery. They also operate MEDIFLIX, a platform dedicated to medical knowledge-sharing. Furthermore, Dong-A Socio Holdings is engaged in the construction of various industrial facilities, such as biotechnology, pharmaceutical, food production, and logistics warehouses, as well as educational, research, commercial, and public infrastructure. This includes comprehensive design, maintenance, and asset development services. Their capabilities also extend to IT systems, providing both development and maintenance solutions.